Teva Pins Long-Term Hopes In MS On Return Of Laquinimod
This article was originally published in Scrip
After missing out on the initial wave of oral multiple sclerosis drugs, Teva Pharmaceutical Industries Ltd. still has its eye on the oral immunomodulator laquinimod as a future pillar for the firm in multiple sclerosis. Teva is hoping for a launch in 2018 after a third and final Phase III trial reads out in 2017.
You may also be interested in...
The company has identified 600 sites of care to treat Alzheimer's patients with aducanumab in the US and is confident on its pricing strategy, management said.
"I don't know why folks are anxious to have a race to the top in terms of rates," Joseph Wolk ways. After US tax reform in 2017, lowering the standard tax rate from 35% to 21%, J&J committed to increasing US investment 15% over the next four years.
J&J employs 3,000 more people today than it did before US corporate tax reform in 2017, CFO Wolk said, highlighting the company's US investments.